Oxford Immuntech financial report

Directors’ Report
PRINCIPAL ACTIVITIES

The company’s principal activity is as a T cell measurement company which has a mission to develop and sell diagnostic products which deal with major unmet medical and scientific needs.

The firm’s primary product is T-SPOT.TB, a diagnostic test for tuberculosis, which is one of the world’s major killers.

BUSINESS REVIEW
The company’s primary product is now being sold throughout Asia, the Middle East and Europe, with the North American market scheduled for this year.

RESULTS
Issued share capital details

A total of 1,265,528 ordinary shares, with an aggregate nominal value of 1,265.528 pounds were issued.

A total of 79,750 ordinary A shares, with an aggregate nominal value of 79.75 pounds were issued.

A total of 903,220 other shares, with an aggregate nominal value of 903.22 pounds were issued.

A total of 3,266,885 other shares, with an aggregate nominal value of 3,266.885 pounds were issued.

A total of 362,020 other shares, with an aggregate nominal value of 362.02 pounds were issued.

A total of 7,612,152 other shares, with an aggregate nominal value of 7612.152 pounds were issued.

There are in excess of 50 shareholders, mixed between private individuals, Oxford University, the Wellcome Trust, private companies and investment funds.

Companies investing include Vitabiotics, the Dow Chemical Company and Mabtech AB.

Employees
OFFICERS OF THE COMPANY

Company secretary: Simon William Turner
Directors: Dr Robert Ian James, Ludwig Michael Steinmetz, Dr Rainer Hebert Strohmenger, Dr Peter James Wrighton-Smith.

Zenopa sourced data on Oxford Immunotec

Oxford Immunotec is an international T cell measurement company with a mission to develop and sell innovative diagnostic products which address major unmet scientific and medical needs.

Its primary product is T-SPOT.TB, a leading diagnostic test for tuberculosis, still one of the world’s major killers. T-SPOT.TB is now being sold through Europe, the Middle East and Asia, with the North American market scheduled for 2008.
The company was founded in 2002, based on world-leading research at the University of Oxford and is headquartered near Oxford, UK.